Description
Drawing on their experience in producing a Cochrane review of neuraminidase inhibitors for influenza, the authors discuss how to improve the reliability of systematic reviewsCitation
Jefferson, T., Doshi, P., Thompson, M., Heneghan, C. (2011). Ensuring safe and effective drugs: who can do what it takes? BMJ, 342. DOI: 10.1136/bmj.c7258Keyword
clinical study reportsneuraminidase inhibitors
research transparency
F. Hoffman-La Roche & Co.
Cochrane Collaboration
Access to Information--legislation & jurisprudence
Clinical Trials as Topic
Drug Industry
Oseltamivir
Review Literature as Topic
Identifier to cite or link to this item
http://hdl.handle.net/10713/6616ae974a485f413a2113503eed53cd6c53
10.1136/bmj.c7258
Scopus Count
Collections
Related articles
- Neuraminidase inhibitors--the story behind the Cochrane review.
- Authors: Doshi P
- Issue date: 2009 Dec 8
- The truth about Tamiflu? Neuraminidase inhibitors in pandemic A/H1N1 flu.
- Authors: Weber JT, Nicoll A, Bridges CB, Ciancio BC
- Issue date: 2010 Jan 13
- Effectiveness of neuraminidase inhibitors for severe influenza.
- Authors: Fry AM
- Issue date: 2014 May
- Oseltamivir resistance: what does it mean clinically?
- Authors: Baum SG
- Issue date: 2009 Dec 15
- Global transmission of oseltamivir-resistant influenza.
- Authors: Moscona A
- Issue date: 2009 Mar 5